InsidersTradesSigma
Total declarations
Companies
▲ Purchases (25 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
25
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-6.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by THEUER CHARLES, Chairman & CEO. Insider active across 2 companies, notably Tracon Pharmaceuticals, Inc.. In total, 28 reports have been published. Breakdown: 25 buys · 0 sell. Total volume traded: €209k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 12 December 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations28 total
9,333 shares@ US$1.14100.0% of flowCommon StockSEC:0001193125-25-320992:0
3,500 shares@ US$0.13770.2% of flowCommon StockSEC:0001415889-24-007846:0
3,999 shares@ US$0.661.1% of flowCommon StockSEC:0001209191-23-025930:0
Ideal exit: 21 Jan 2024 (T+270)
200 shares@ US$1.520.1% of flowCommon StockSEC:0001209191-23-014434:0
Ideal exit: 25 Nov 2023 (T+270)
6,800 shares@ US$1.624.9% of flowCommon StockSEC:0001209191-23-003934:0
Ideal exit: 15 Oct 2023 (T+270)
23,000 shares@ US$1.293713.3% of flowCommon StockSEC:0001209191-22-061329:0
Ideal exit: 10 Sept 2023 (T+270)
13,900 shares@ US$1.419.0% of flowCommon StockSEC:0001209191-22-058302:0
Ideal exit: 15 Aug 2023 (T+270)
9,200 shares@ US$1.526.8% of flowCommon StockSEC:0001209191-22-055687:0
Ideal exit: 31 Jul 2023 (T+270)
6,000 shares@ US$1.594.6% of flowCommon StockSEC:0001209191-22-055435:0
Ideal exit: 30 Jul 2023 (T+270)
5,000 shares@ US$1.774.3% of flowCommon StockSEC:0001209191-22-053202:0
Ideal exit: 4 Jul 2023 (T+270)
5,000 shares@ US$1.674.0% of flowCommon StockSEC:0001209191-22-052605:0
Ideal exit: 30 Jun 2023 (T+270)
5,000 shares@ US$1.764.3% of flowCommon StockSEC:0001209191-22-051200:0
Ideal exit: 19 Jun 2023 (T+270)
4,500 shares@ US$1.853.9% of flowCommon StockSEC:0001209191-22-043061:0
Ideal exit: 18 Apr 2023 (T+270)
3,000 shares@ US$1.872.7% of flowCommon StockSEC:0001209191-22-042093:0
Ideal exit: 8 Apr 2023 (T+270)
10,000 shares@ US$1.8520.5% of flowCommon StockSEC:0001209191-22-028188:0
Ideal exit: 3 Feb 2023 (T+270)
2,500 shares@ US$1.975.5% of flowCommon StockSEC:0001209191-22-027975:0
Ideal exit: 31 Jan 2023 (T+270)
5,000 shares@ US$1.970911.0% of flowCommon StockSEC:0001209191-22-026562:0
Ideal exit: 24 Jan 2023 (T+270)
4,500 shares@ US$2.3011.2% of flowCommon StockSEC:0001209191-22-025471:0
Ideal exit: 16 Jan 2023 (T+270)
2,000 shares@ US$2.505.4% of flowCommon StockSEC:0001209191-22-024070:0
Ideal exit: 3 Jan 2023 (T+270)
4,000 shares@ US$2.7011.3% of flowCommon StockSEC:0001209191-22-021876:0
Ideal exit: 25 Dec 2022 (T+270)
1,200 shares@ US$2.453.1% of flowCommon StockSEC:0001209191-22-020678:0
Ideal exit: 16 Dec 2022 (T+270)
681 shares@ US$2.880.8% of flowCommon StockSEC:0001209191-21-066096
Ideal exit: 15 Aug 2022 (T+270)
681 shares@ US$2.882.0% of flowCommon StockSEC:0001209191-21-066096:0
Ideal exit: 15 Aug 2022 (T+270)
1,000 shares@ US$3.413.4% of flowCommon StockSEC:0001209191-21-063520:0
Ideal exit: 2 Aug 2022 (T+270)
1,000 shares@ US$3.411.4% of flowCommon StockSEC:0001209191-21-063520
Ideal exit: 2 Aug 2022 (T+270)
25 of 28 declarations
About THEUER CHARLES
Charles Theuer is the Chairman and CEO of Tracon Pharmaceuticals, Inc. He leads the company in the development of innovative cancer treatments. Under his leadership, Tracon aims to improve patient outcomes through targeted therapies. Charles Theuer has extensive experience in the pharmaceutical sector, contributing to the company's strategy and vision.
